The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL OMB 3235-Number: 0076 Estimated average burden hours per response: 4.00

1. Issuer's Identity

CIK (Filer ID Nur	nber)	Previous Names	None		Entity Type
<u>0001394319</u>	Ti	racon Pharn	naceuticals Inc		X Corporation
Name of Issue	r Le	exington Ph	armaceuticals, Inc		Limited Partnership
Tracon Pharmaceuticals, Inc					Limited Liability Company
Jurisdiction o					General Partnership
Incorporation/Orgai DELAWARE	lization				Business Trust
Vear of Incorpora	tion/Organizatio	n			Other (Specify)
-	tion/Organizatio	11			
X Over Five Years Ago Within Last Five Years (S	necify Vear)				
Yet to Be Formed	specify real)				
Tet to be I office					
2. Principal Place of Busines	s and Contact Info	ormation			
Name	of Issuer				
Tracon Pharmaceuticals, Inc					
	Address 1			Street A	Address 2
4350 LA JOLLA VILLAGE			SUITE 800		
City	State/Provinc	e/Country			Phone Number of Issuer
San Diego	CALIFORNIA		92122		858-550-0780
3. Related Persons					
Last Name		First	t Name		Middle Name
THEUER	CHAR	LES		P.	
Street Address 1		Street A	Address 2		
C/O TRACON PHARMACEUTICALS, IN		LA JOLLA	VILLAGE DR, ST	ΓE	
City		State/Prov	ince/Country		ZIP/PostalCode
SAN DIEGO	CALIF	FORNIA		92122	
Relationship: X Executive	Officer X Directo	r Promote	er		
Clarification of Response (if	Necessary):				

Last Name	First Name		Middle Name
BITAR	PATRICIA	L.	
Street Address 1	Street Address 2		
C/O TRACON	4350 LA JOLLA VILLAGE DR, ST	Έ	
PHARMACEUTICALS, INC.	800		
City	State/Province/Country		ZIP/PostalCode
SAN DIEGO	CALIFORNIA	92122	
Relationship: X Executive Officer	Director Promoter		

Clarification of Response (if Necessary):

Last Name	First Name	Middle Name
LOGAN	Н	CASEY
Street Address 1	Street Address 2	
C/O TRACON	4350 LA JOLLA VILLAGE DR, S	TE
PHARMACEUTICALS, INC.	800	
City	State/Province/Country	ZIP/PostalCode
SAN DIEGO	CALIFORNIA	92122
Relationship: X Executive Office	r Director Promoter	
Clarification of Response (if Neces	ssary):	
Last Name	First Name	Middle Name
LARUE	WILLIAM	
Street Address 1	Street Address 2	
C/O TRACON	4350 LA JOLLA VILLAGE DR, S	TE
PHARMACEUTICALS, INC.	800	
City	State/Province/Country	ZIP/PostalCode
SAN DIEGO	CALIFORNIA	92122
Last Name	First Name	Middle Name
MATTINGLY	MARTIN	
Street Address 1	Street Address 2	
C/O TRACON PHARMACEUTICALS, INC.	4350 LA JOLLA VILLAGE DR, S 800	TE
City	State/Province/Country	ZIP/PostalCode
SAN DIEGO	CALIFORNIA	92122
Relationship: Executive Officer	X Director Promoter	
Clarification of Response (if Neces	ssary):	
Last Name	First Name	Middle Name
TWIFORD	J.	RAINER
Street Address 1	Street Address 2	
C/O TRACON PHARMACEUTICALS, INC.	4350 LA JOLLA VILLAGE DR, S 800	TE
City	State/Province/Country	ZIP/PostalCode
SAN DIEGO	CALIFORNIA	92122

Clarification of Response (if Necessary):

Relationship: Executive Officer X Director Promoter

Last Name	First Name		Middle Name
WALKER	PAUL		
Street Address 1	Street Address 2		
C/O TRACON PHARMACEUTICALS, INC.	4350 LA JOLLA VILLAGE DR, ST 800	Έ	
City	State/Province/Country		ZIP/PostalCode
SAN DIEGO	CALIFORNIA	92122	
Relationship: Executive Officer	X Director Promoter		

Clarification of Response (if Necessary):

Last Name **First Name** Middle Name WORLAND **STEPHEN Street Address 1 Street Address 2** C/O TRACON 4350 LA JOLLA VILLAGE DR, STE PHARMACEUTICALS, INC. 800 **ZIP/PostalCode** City State/Province/Country SAN DIEGO CALIFORNIA 92122 Relationship: Executive Officer X Director Promoter

Clarification of Response (if Necessary):

4. Industry Group

Agriculture Banking & Financial Services Commercial Banking Insurance Investing Investment Banking Pooled Investment Fund		Health Care X Biotechnology Health Insurance Hospitals & Physicians Pharmaceuticals Other Health Care	Retailing Restaurants Technology Computers Telecommunications Other Technology
Is the issuer regis an investment con the Investment Co Act of 1940? Yes Other Banking &	npany under	Manufacturing Real Estate Commercial Construction REITS & Finance	Travel Airlines & Airports Lodging & Conventions Tourism & Travel Services Other Travel
Business Services Energy Coal Mining		Residential Other Real Estate	Other

Other Energy

Oil & Gas

Electric Utilities

Energy Conservation Environmental Services

5. Issuer Size

Revenue Range	OR	Aggregate Net Asset Value Range
No Revenues		No Aggregate Net Asset Value
\$1 - \$1,000,000		\$1 - \$5,000,000
\$1,000,001 - \$5,000,000		\$5,000,001 - \$25,000,000
\$5,000,001 - \$25,000,000		\$25,000,001 - \$50,000,000
\$25,000,001 - \$100,000,000		\$50,000,001 - \$100,000,000
Over \$100,000,000		Over \$100,000,000
X Decline to Disclose		Decline to Disclose
Not Applicable		Not Applicable

6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

Rule 504(b)(1) (not (i), (ii) or (iii))	Investment Company	Investment Company Act Section 3(c)			
Rule 504 (b)(1)(i) Rule 504 (b)(1)(ii)	Section 3(c)(1)	Section 3(c)(9)			
Rule 504 (b)(1)(iii)	Section 3(c)(2)	Section $3(c)(10)$			

Rule 505 X Rule 506(b) Rule 506(c) Securities Act Section 4(a)(5)	Section 3(c) Section 3(c) Section 3(c) Section 3(c) Section 3(c)	 (4) Section (5) Section (6) Section 	n 3(c)(11) n 3(c)(12) n 3(c)(13) n 3(c)(14)	
7. Type of Filing				
X New Notice Date of First Sale 2017-03-14 Amendment	First Sale Yet to	Occur		
8. Duration of Offering				
Does the Issuer intend this offering to last more t	han one year? X	Yes No		
9. Type(s) of Securities Offered (select all that ap	ply)			
X Equity Debt Option, Warrant or Other Right to Acquire An Security to be Acquired Upon Exercise of Opt Other Right to Acquire Security	•	Pooled Investmen Tenant-in-Commo Mineral Property Other (describe)	on Securities	
10. Business Combination Transaction				
Is this offering being made in connection with a land a merger, acquisition or exchange offer?	business combina	tion transaction, suc	ch as Yes X No	
Clarification of Response (if Necessary):				
11. Minimum Investment				
Minimum investment accepted from any outside	investor \$0 USD			
12. Sales Compensation				
Recipient	Recip	ient CRD Number 2	X None	
(Associated) Broker or Dealer X None	(Asso	ciated) Broker or De	ealer CRD Number X Non	e
Street Address 1		Street A	Address 2	
City State(s) of Solicitation (select all that apply) Check "All States" or check individual States		Province/Country eign/non-US		ZIP/Postal Code
13. Offering and Sales Amounts				
Total Offering Amount\$21,000,000 USD oTotal Amount Sold\$1,000,000 USDTotal Remaining to be Sold \$20,000,000 USD oClarification of Response (if Necessary):14. Investors				
Select if securities in the offering have been or	r may be sold to p	persons who do not	qualify as accredited	

investors, and enter the number of such non-accredited investors who already have invested in the offering. Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

1

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions	\$0 USD	Estimate
Finders' Fees	\$0 USD	Estimate

Clarification of Response (if Necessary):

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$0 USD Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Regulation D exemption for the offering, the issuer is not disqualified from relying on Regulation D for one of the reasons stated in Rule 505(b)(2)(iii) or Rule 506(d).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
Tracon Pharmaceuticals, Inc.	/s/ Patrici L. Bitar	Patricia L. Bitar	CFO	2017-05-09

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.